Overview

MDD POC Study GSK372475 Subjects Depressive Disease

Status:
Completed
Trial end date:
2008-10-15
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy, safety and tolerability of GSK372475 compared with placebo in the treatment of outpatients subjects with major depressive disorder to exhibit decreased pleasure, interest and energy.
Phase:
Phase 2
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Paroxetine